echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Nature Index-China: Alzheimer's disease drug trial explores the connection between the gut and the brain

    Nature Index-China: Alzheimer's disease drug trial explores the connection between the gut and the brain

    • Last Update: 2021-06-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The supplement "2021 China Nature Index" published on May 27th, based on the Nature Index data, shows China’s latest scientific research output in the field of natural sciences, and reveals the flow of Chinese scientific talents and international scientific research cooperation.


    Among them, the article "Alzheimer's disease drug trial explores the relationship between the intestine and the brain" provides an in-depth report on the ninth phase one research and development team, showing the successful course of Professor Geng Meiyu and his team's 22-year research and development phase IX one.


    Alzheimer's disease drug trial explores the connection between the gut and the brain

    Alzheimer's disease drug trial explores the connection between the gut and the brain

    With the help of new research methods to explore the relationship between the intestine and the brain, an innovative drug for Alzheimer's disease from China has provided us with new clues.


    Looking at the world, dementia affects approximately 50 million people, and this number continues to grow at a rate of 10 million per year, more than half of which is attributed to Alzheimer’s disease.


    Reshaping Alzheimer's disease treatment options

    Reshaping Alzheimer's disease treatment options

    Traditional Alzheimer's disease drug research often focuses on the accumulation of β-amyloid in the brain and the neurofibrillary tangles caused by the hyperphosphorylation of Tau protein.


    In 1997, Professor Geng Meiyu began to search for a sugar chain compound that would compete with glycosaminoglycans during the formation of β-amyloid fiber, thereby inhibiting the toxicity of β-amyloid fiber and reducing its presence in the brain.


    She has extensively investigated a series of related factors and studies focusing on the association between Alzheimer's disease and intestinal flora.


    Through cooperation with the Chinese pharmaceutical company Green Valley Pharmaceuticals, Geng Meiyu's 22-year research effort finally bears fruit.


    Compared with drugs based on proteins and nucleic acids, the challenge of producing Manlutner capsules lies in the high structural complexity and diversity of sugar drugs.


    Work together to create the future

    Work together to create the future

    In 2019, Professor Geng Meiyu published in the journal Cell Research about the effects of a pair of mice in Phase 9 and the relationship between the dynamic changes of intestinal flora and neuroinflammation at different stages of Alzheimer's disease Research results.


    However, this paper triggered a comment from an editor of the journal Cell Research, questioning the multiple targets claimed in the paper that can produce the therapeutic effect, and why there is no explanation of related side effects.


    Professor Geng Meiyu explained that the research and development of Phase 9 and 1 proves that the development focus of China's pharmaceutical industry is shifting from the development of generic drugs to the development of original research drugs.


    In a response article published in the journal Cell Research, Professor Geng Meiyu listed other multi-targeted drugs, such as metformin, a widely used oral drug for type II diabetes that targets multiple pathways to achieve The expected therapeutic effect.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.